Page last updated: 2024-11-13

bmn 111

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vosoritide: a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral ossification [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119058036
MeSH IDM0581404

Synonyms (9)

Synonym
gtpl9068
1480724-61-5
bmn 111
unii-7se5582q2p
7se5582q2p ,
vosoritide [usan:inn]
vosoritide
bmn-111
voxzogo

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No new adverse effects of vosoritide were detected."( Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Alanay, Y; Arundel, P; Bacino, CA; Basel, D; Bober, MB; Charrow, J; Day, JRS; Fisheleva, E; Font, RU; Ginebreda, I; Harmatz, P; Hoernschemeyer, D; Hoover-Fong, J; Huntsman-Labed, A; Irving, M; Jayaram, K; Kotani, Y; Leiva-Gea, A; Luna-González, F; Mochizuki, H; Mohnike, K; Ozono, K; Polgreen, LE; Porco, DM; Rutsch, F; Saal, HM; Savarirayan, R; Tofts, L; White, KK; Wilcox, WR; Yasui, N, 2021
)
0.62
"Vosoritide treatment has safe and persistent growth-promoting effects in children with achondroplasia treated daily for two years."( Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Alanay, Y; Arundel, P; Bacino, CA; Basel, D; Bober, MB; Charrow, J; Day, JRS; Fisheleva, E; Font, RU; Ginebreda, I; Harmatz, P; Hoernschemeyer, D; Hoover-Fong, J; Huntsman-Labed, A; Irving, M; Jayaram, K; Kotani, Y; Leiva-Gea, A; Luna-González, F; Mochizuki, H; Mohnike, K; Ozono, K; Polgreen, LE; Porco, DM; Rutsch, F; Saal, HM; Savarirayan, R; Tofts, L; White, KK; Wilcox, WR; Yasui, N, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345469Human Guanylyl cyclase-B (Receptor Guanylyl Cyclase (RGC) family)2012American journal of human genetics, Dec-07, Volume: 91, Issue:6
Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (35.29)24.3611
2020's11 (64.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.58 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (27.78%)5.53%
Reviews4 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]